Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
Updated
Grant from the National Institutes of Health, open to small businesses. Closes Oct 20, 2027, 365 days left.
| Opportunity number | PAR-25-225 |
|---|---|
| Agency | National Institutes of Health |
| Funding type | Grant |
| Field | Health |
| Cost sharing or matching | Not required |
| Assistance listing | 93.853 |
| Posted | Nov 4, 2024 |
| Closes | Oct 20, 2027 (365 days left) |
| Add the deadline to | Google Calendar |
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state controlled institutions of higher education
- Native American tribal governments (federally recognized)
- Public housing authorities and Indian housing authorities
- Native American tribal organizations (other than federally recognized tribal governments)
- Nonprofits with 501(c)(3) status, other than institutions of higher education
- Nonprofits without 501(c)(3) status, other than institutions of higher education
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others (see the eligibility notes)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Description
Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products.
This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.
Full announcement and how to apply on Grants.gov
Health grants right now
There are 350 open federal grants in health that small businesses may apply for; 33 close within 30 days. The median award ceiling is $500,000. The agencies offering the most are National Institutes of Health, Centers for Disease Control and Prevention - ERA and Centers for Disease Control - NCBDDD. Grants in this field stay open a median of 1031 days; this one is open for 1080 days.
Who has won this program before
- University Of North Carolina AT Chapel Hill $977.0 million · from Jun 29, 2006
- Mayo Clinic $102.2 million · from Sep 15, 2019
- The General Hospital Corporation $75.4 million · from Sep 19, 2019
- Research Triangle Institute $72.7 million · from Apr 1, 2018
- Yale Univ $67.5 million · from Jul 1, 2015
The largest grants and cooperative agreements under assistance listing 93.853 with payments since Oct 1, 2025, from USAspending.gov. Amounts are each award's total.
Other open grants in the same program
Under assistance listing 93.853, the federal program this grant is paid from.
More open grants from the National Institutes of Health
340 open grants from this agency accept small businesses, with $356.4 million in total program funding listed.